Spierings NMK, et al. - Using PubMed and MEDLINE, researchers performed a literature review to critically assess the clinical trial evidence for different treatment modalities for melasma [an acquired disorder of facial pigmentation], published over the past 10 years in peer-reviewed journals. The search was carried out in July 2019, and search parameters were limited to all articles published in the English language in the last 10 years only. There were 89 clinical trials. Topical HQ and retinoid-based therapy should be first-line for at least 3 months with the addition of oral tranexamic acid at 250 mg BD if no contraindication is present. LFQS Nd:YAG, picosecond laser, and the pulsed dye laser in lighter skin types are used in second‐line laser therapy. Third‐line therapy would be the addition of chemical peels to the treatments described above, with GA or TCA peels having the most evidence for effectiveness.